SCHEMBL9843191

SCHEMBL9843191

CC#Cc1ccc([N+](=O)[O-])cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.52
HSD17B10 Q99714 2/20 0.52
ACHE P22303 1/20 0.52
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
RECQL P46063 1/20 0.47
MAPT P10636 4/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HSP90AA1 P07900 1/20 0.46
OPRK1 P41145 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
MAPK1 P28482 1/20 0.45
LMNA P02545 1/20 0.44
CES1 P23141 1/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP1B1 Q16678 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27781073 0.98 ALDH1A1 (0.50) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL19929693 0.88 CASP3 (0.53) ALDH1A1HSD17B10ACHECASP3SENP8
Diethylamine SCHEMBL27944587 0.88 MAPT (0.50) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL14664048 0.86 CASP3 (0.63) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL5959613 0.81 ALDH1A1 (0.75) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL12207815 0.79 CASP3 (0.49) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL28696930 0.78 CASP3 (0.51) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL4521413 0.78 CASP3 (0.51) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL7803648 0.78 CASP3 (0.66) ALDH1A1HSD17B10ACHECASP3SENP8
SCHEMBL10625611 0.78 CASP3 (0.51) ALDH1A1HSD17B10ACHECASP3SENP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3481819-B1 COMPOUNDS AND THEIR USE FOR REDUCING URIC ACID LEVELS ACQUIST LLC (US) 2022-06-01 EP disclosed
US-20220024900-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2022-01-27 US disclosed
CN-109476642-B Compounds and their use for reducing uric acid levels 阿奎斯特有限责任公司 2022-01-25 CN disclosed
US-11168075-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-11-09 US disclosed
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2021-08-05 US disclosed
US-11020397-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2021-06-01 US disclosed
US-20200347034-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2020-11-05 US disclosed
US-10759784-B2 Compounds and their use for reducing uric acid levels ACQUIST LLC (US) 2020-09-01 US disclosed
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC (US) 2020-08-27 US disclosed
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels ACQUIST LLC 2020-06-25 US disclosed
US-8507464-B2 Phosphoramidate alkylator prodrugs THRESHOLD PHARMACEUTICALS, INC. (US) 2013-08-13 US disclosed
US-20130144102-A1 CATALYSTS FOR THE ALKYNE METATHESIS STUDIENGESELLSCHAFT KOHLE MBH (DE) 2013-06-06 US disclosed
US-20130144102-A1 CATALYSTS FOR THE ALKYNE METATHESIS STUDIENGESELLSCHAFT KOHLE MBH (DE) 2013-06-06 US disclosed
US-20110251159-A1 Phosphoramidate Alkylator Prodrugs THRESHOLD PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
US-8003625-B2 Phosphoramidate alkylator prodrugs THRESHOLD PHARMACEUTICALS, INC. (US) 2011-08-23 US disclosed
US-8003625-B2 Phosphoramidate alkylator prodrugs THRESHOLD PHARMACEUTICALS, INC. (US) 2011-08-23 US disclosed
US-20100137254-A1 PHOSPHORAMIDATE ALKYLATOR PRODRUGS IMMUNOGENESIS, INC. 2010-06-03 US disclosed
US-20100137254-A1 PHOSPHORAMIDATE ALKYLATOR PRODRUGS IMMUNOGENESIS, INC. 2010-06-03 US disclosed
WO-2007002931-A2 PHOSPHORAMIDATE ALKYLATOR PRODRUGS THRESHOLD PHARMACEUTICALS, INC. (US) 2007-01-04 WO disclosed
EP-0420699-A2 Ferromagnetic member consiting of organic material CANON KABUSHIKI KAISHA (JP) 1991-04-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137254-A1 PHOSPHORAMIDATE ALKYLATOR PRODRUGS TYMP, PAICS, PNP ALDH1A1 1886/4885HSD17B10 4022/4885ACHE 4710/4885
US-20200347034-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, PON1 ALDH1A1 192/4885HSD17B10 902/4885ACHE 1525/4885
US-20220024900-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, PON1 ALDH1A1 192/4885HSD17B10 902/4885ACHE 1525/4885
US-11168075-B2 Compounds and their use for reducing uric acid levels XDH, OAT, PON1 ALDH1A1 192/4885HSD17B10 902/4885ACHE 1525/4885
US-20110251159-A1 Phosphoramidate Alkylator Prodrugs TYMP, PAICS, PNP ALDH1A1 1961/4885HSD17B10 4005/4885ACHE 4749/4885
US-20210236495-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 ALDH1A1 226/4885HSD17B10 837/4885ACHE 1211/4885
US-20200268757-A1 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 ALDH1A1 226/4885HSD17B10 837/4885ACHE 1211/4885
US-20130144102-A1 CATALYSTS FOR THE ALKYNE METATHESIS MSH6, AP3M1, PMS2 ALDH1A1 1300/4885HSD17B10 1750/4885ACHE 1185/4885
US-10759784-B2 Compounds and their use for reducing uric acid levels XDH, OAT, PON1 ALDH1A1 192/4885HSD17B10 902/4885ACHE 1525/4885
US-11020397-B2 Compounds and their use for reducing uric acid levels XDH, OAT, UGT2B7 ALDH1A1 95/4885HSD17B10 849/4885ACHE 1277/4885
US-20200197393-A9 Compounds and Their Use for Reducing Uric Acid Levels XDH, OAT, URB2 ALDH1A1 226/4885HSD17B10 837/4885ACHE 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.